Literature DB >> 23625450

All anterior and bileaflet mitral valve prolapses are repairable in the modern era of reconstructive surgery.

Javier G Castillo1, Anelechi C Anyanwu, Ahmed El-Eshmawi, David H Adams.   

Abstract

OBJECTIVE: Although mitral valve repair is the preferred treatment for degenerative mitral valve disease, valve replacement still remains prevalent, particularly in the setting of anterior leaflet prolapse. We sought to determine the feasibility and mid-term durability of a lesion-based surgical strategy applied systematically in a consecutive and nonexclusionary (all comers) series of patients with degenerative mitral valve disease and either isolated anterior leaflet or bileaflet prolapse.
METHODS: From January 2002 to December 2010, 188 consecutive patients [mean age 56 ± 14 years (range 12-86), 31% female, mean left ventricular ejection fraction 55 ± 9%] underwent surgery for degenerative anterior mitral leaflet prolapse [isolated (n = 42, 22%) or bileaflet prolapse (n = 146, 78%)]. Degenerative aetiology was Barlow's disease in 110 (58%) patients and fibroelastic deficiency in 78 (42%).
RESULTS: Patients with anterior leaflet prolapse were significantly more symptomatic (New York Heart Association functional Class III-IV) than those with bileaflet prolapse (28.6 vs 9.6%; P = 0.003) at the time of surgery. All patients underwent mitral valve repair and ring annuloplasty. There was 1 immediate valve replacement due to atrioventricular groove bleeding and consequent haematoma in an elderly female patient (99.5% repair rate). Predominant repair techniques were polytetrafluoroethylene neochordoplasty (or loop technique) in 93 (49%) patients, chordal transfer in 86 (46%) and posterior leaflet flip technique in 21 (11%). Median length of stay was 6 (interquartile 5-8) days. In-hospital mortality was 1% (n = 2). Predischarge transthoracic echocardiography showed none to trace mitral regurgitation in 91% of the patients and mild mitral regurgitation in 9%. The Kaplan-Meier estimates for cumulative survival at 1 and 7 years were 98.4 ± 0.9 and 88.7 ± 2.2%, respectively. Freedom from ≥ moderate mitral regurgitation was 100% at 1 year, 93.7 ± 2.2% at 4 years and 90.3 ± 3.7% at 7 years. When the interval-censored estimator was used, freedom from ≥ moderate mitral regurgitation at 1, 4 and 7 years was 100, 96 and 92%, respectively.
CONCLUSION: A lesion-based surgical approach with an intention to repair all degenerative valves with anterior leaflet prolapse was applied to a consecutive series of patients with degenerative mitral valve disease. We were able to achieve a near-100% repair rate. Repair of all degenerative valves may be feasible with good mid-term durability, regardless of valve morphology, patient age or comorbidities.

Entities:  

Keywords:  Anterior leaflet; Mitral; Outcomes; Repair; Valve disease

Mesh:

Year:  2013        PMID: 23625450     DOI: 10.1093/ejcts/ezt196

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  13 in total

1.  Minimally invasive mitral valve surgery: "The Leipzig experience".

Authors:  Piroze M Davierwala; Joerg Seeburger; Bettina Pfannmueller; Jens Garbade; Martin Misfeld; Michael A Borger; Friedrich W Mohr
Journal:  Ann Cardiothorac Surg       Date:  2013-11

2.  Barlow's mitral valve disease: results of conventional and minimally invasive repair approaches.

Authors:  Serguei I Melnitchouk; Joerg Seeburger; Anna F Kaeding; Martin Misfeld; Friedrich W Mohr; Michael A Borger
Journal:  Ann Cardiothorac Surg       Date:  2013-11

Review 3.  Current Discoveries and Interventions for Barlow's Disease.

Authors:  Juan A Siordia
Journal:  Curr Cardiol Rep       Date:  2016-08       Impact factor: 2.931

4.  Anterior versus posterior leaflet mitral valve repair: A propensity-matched analysis.

Authors:  Alexander A Brescia; Tessa M F Watt; Liza M Rosenbloom; Shannon L Murray; Xiaoting Wu; Matthew A Romano; Steven F Bolling
Journal:  J Thorac Cardiovasc Surg       Date:  2020-03-05       Impact factor: 6.439

Review 5.  Management of organic mitral regurgitation: guideline recommendations and controversies.

Authors:  Maria-Magdalena Gurzun; Andreea C Popescu; Carmen Ginghina; Bogdan A Popescu
Journal:  Korean Circ J       Date:  2015-03-24       Impact factor: 3.243

6.  New insights into mitral heart valve prolapse after chordae rupture through fluid-structure interaction computational modeling.

Authors:  Andrés Caballero; Wenbin Mao; Raymond McKay; Charles Primiano; Sabet Hashim; Wei Sun
Journal:  Sci Rep       Date:  2018-11-23       Impact factor: 4.379

7.  Comparison of early postoperative results between conventional and transapical mitral valve repair.

Authors:  Aleksejus Zorinas; Artūras Lipnevicius; Viktorija Bleizgytė; Vilius Janušauskas; Daina Liekienė; Mindaugas Budra; Robertas Stasys Samalavičius; Agnė Drąsutienė; Diana Zakarkaitė; Audrius Aidietis; Kęstutis Ručinskas
Journal:  Postepy Kardiol Interwencyjnej       Date:  2019-12-08       Impact factor: 1.426

8.  Recurrent mitral regurgitation after mitral valve repair for bileaflet lesions in the modern era.

Authors:  Daisuke Kaneyuki; Hiroyuki Nakajima; Toshihisa Asakura; Akihiro Yoshitake; Chiho Tokunaga; Masato Tochii; Jun Hayashi; Akitoshi Takazawa; Hiroaki Izumida; Atsushi Iguchi
Journal:  J Cardiothorac Surg       Date:  2019-11-27       Impact factor: 1.637

9.  Comparison of the Outcomes of Modified Artificial Chordae Technique for Mitral Regurgitation through Right Minithoracotomy or Median Sternotomy.

Authors:  Zhao-Lei Jiang; Xiao-Yuan Feng; Nan Ma; Jia-Quan Zhu; Li Zhang; Fang-Bao Ding; Chun-Rong Bao; Ju Mei
Journal:  Chin Med J (Engl)       Date:  2016-09-20       Impact factor: 2.628

10.  Long-Term Results of Mitral Valve Repair.

Authors:  Francisco Diniz Affonso da Costa; Daniele de Fátima Fornazari Colatusso; Gustavo Luis do Santos Martin; Kallyne Carolina Silva Parra; Mariana Cozer Botta; Eduardo Mendel Balbi Filho; Myrian Veloso; Gabriela Miotto; Andreia Dumsch de Aragon Ferreira; Claudinei Colatusso
Journal:  Braz J Cardiovasc Surg       Date:  2018 Jan-Feb
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.